Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 772.00 INR
Change Today 0.00 / 0.00%
Volume 0.0
HCBA On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:27 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

novartis india ltd (HCBA) Snapshot

Open
779.45
Previous Close
778.45
Day High
784.75
Day Low
765.00
52 Week High
06/11/15 - 869.60
52 Week Low
03/27/15 - 539.95
Market Cap
24.7B
Average Volume 10 Days
41.5K
EPS TTM
26.28
Shares Outstanding
32.0M
EX-Date
07/14/15
P/E TM
29.4x
Dividend
10.00
Dividend Yield
1.30%
Current Stock Chart for NOVARTIS INDIA LTD (HCBA)

Related News

No related news articles were found.

novartis india ltd (HCBA) Related Businessweek News

No Related Businessweek News Found

novartis india ltd (HCBA) Details

Novartis India Limited manufactures and sells healthcare products in India and internationally. It operates through four segments: Pharmaceuticals, Generics, Over-The-Counter, and Animal Health. The Pharmaceuticals segment offers a portfolio of prescription medicines through healthcare professionals. The Generics segment offers retail generics products in various therapeutic areas, such as anti-TB, anti-DUB (gynecology), anti-histamines, antibiotics, anti-ulcerants, anti-diabetes, and cardiovascular. The Over-The-Counter segment offers vitamins, minerals, and nutritional supplements, as well as products for the treatment of cough, cold, and allergy. The Animal Health segment offers products for the cattle and poultry markets. The company was founded in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.

1,207 Employees
Last Reported Date: 05/27/15
Founded in 1947

novartis india ltd (HCBA) Top Compensated Officers

Vice Chairman, Managing Director and Member o...
Total Annual Compensation: 17.0M
Chief Financial Officer
Total Annual Compensation: 7.5M
Whole Time Director
Total Annual Compensation: 5.3M
Compliance Officer and Company Secretary
Total Annual Compensation: 4.7M
Executive Officer of OTC
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

novartis india ltd (HCBA) Key Developments

Novartis AG Reportedly Mulls Acquisition Of Novartis India

Novartis AG (SWX:NOVN) is mulling the acquisition of remaining stake in Novartis India Limited (BSE:500672) and delisting it, sources informed. Novartis executives met investment banks to discuss the procedures if it decides to pursue the delisting, sources said. Dermot Doherty, a spokesman for Novartis, declined to comment to Bloomberg.

Novartis India Ltd Recommends Dividend for the Fiscal Year 2015

Novartis India Ltd. announced that the Board of Directors of the company at its meeting held on May 27, 2015, has considered and approved the dividend recommendation of INR 10 per equity share of INR 5 each for the year ended March 31, 2015.

Novartis India Limited Reports Unaudited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

Novartis India Limited reported unaudited standalone earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 2,023.8 million compared to INR 1,930.3 million a year ago. Profit from operations before other income and finance costs of INR 161.4 million compared to INR 65.1 million a year ago. Profit from ordinary activities before tax was INR 529.1 million compared to INR 322.6 million a year ago. Net profit for the period was INR 519.4 million compared to INR 238.8 million a year ago. Basic and diluted earnings per share after extraordinary items were INR 16.25 compared to INR 7.47 per share a year ago. Basic and diluted earnings per share before extraordinary items were INR 16.30 compared to INR 7.47 per share a year ago. For the full year, the company reported net sales/income from operations (net of excise duty) of INR 8,452.9 million compared to INR 8,397.8 million a year ago. Loss from operations before other income and finance costs of INR 78.7 million compared to INR 49.5 million a year ago. Profit from ordinary activities before tax was INR 995.6 million compared to INR 899.0 million a year ago. Net profit for the period was INR 791.1 million compared to INR 985.3 million a year ago. Basic and diluted earnings per share after extraordinary items were INR 24.75 compared to INR 30.83 per share a year ago. Basic and diluted earnings per share before extraordinary items were INR 26.28 compared to INR 30.83 per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HCBA:IN 772.00 INR -6.45

HCBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HCBA.
View Industry Companies
 

Industry Analysis

HCBA

Industry Average

Valuation HCBA Industry Range
Price/Earnings 30.5x
Price/Sales 3.2x
Price/Book 2.4x
Price/Cash Flow 29.3x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS INDIA LTD, please visit www.novartis.in/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.